1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Pembrolizumab in Early Triple-Negative Breast Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Protocol: Pembrolizumab in Early Triple-Negative Breast Cancer

New Protocol: Pembrolizumab in Early Triple-Negative Breast Cancer
Study:
  • Randomized, double-blind, placebo-controlled trial (KEYNOTE-522)
  • Previously untreated stage II or III triple-negative breast cancer
  • Neoadjuvant/adjuvant pembrolizumab (n=784) or placebo (n=390) plus standard therapy
Efficacy:
  • 36-mo-EFS: 84.5% [81.7%-86.9%] vs 76.8% [72.2%-80.7%], HR: 0.63 [0.48 – 0.82, p<0.001]
  • 36-mo-OS: 89.7% vs 86.9%
Safety:
  • Grade 3 AE >= 77.1% vs 73.3%
  • Discontinuation of the trial regimen: 27.7% vs 14.1%
  • Serious treatment-related AE: 34.1% vs 20.1%

N Engl J Med. 2022 Feb 10;386(6):556-567.

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

https://doi.org/10.1056/nejmoa2112651

Reviewed by Hasan Cagri Yildirim

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More